MedMira
Tracked across 1 events · 6 articles · First seen Jun 30, 2026 · Last active Jun 30, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: MedMira reported increased revenue and gross profit in Q3 FY2026 compared to previous periods, but also a net loss and increased working capital deficit. The company is advancing regulatory approvals for its Multiplo Complete Syphilis Antibody Test and expanding into international markets.
Jun 30, 2026 · 6 articles
80
MedMira advanced regulatory process Canada — Health CanadaMedMira Q3 FY2026 Earnings Report
70
MedMira reported financial resultsMedMira Q3 FY2026 Earnings Report
70
MedMira completed clinical trialsMedMira Q3 FY2026 Earnings Report
70
MedMira increased working capital deficitMedMira Q3 FY2026 Earnings Report
60
MedMira initiated regulatory process AustraliaMedMira Q3 FY2026 Earnings Report
ERGEN INTELLIGENCE
Track MedMira live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard